An Opposite-Direction Modulation of the COMT Val158Met Polymorphism on the Clinical Response to Intrathecal Morphine and Triptans-Reference-Cited by-同舟云学术

An Opposite-Direction Modulation of the COMT Val158Met Polymorphism on the Clinical Response to Intrathecal Morphine and Triptans

Published:2013-10 Issue:10 Volume:14 Page:1097-1106
ISSN:1526-5900
Container-title:The Journal of Pain
language:en
Short-container-title:The Journal of Pain

Author:

Cargnin Sarah,Magnani Francesco,Viana Michele,Tassorelli Cristina,Mittino Daniela,Cantello Roberto,Sances Grazia,Nappi Giuseppe,Canonico Pier Luigi,Genazzani Armando A.,Raffaeli William,Terrazzino Salvatore

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Clinical Neurology,Neurology

Reference58 articles.

1. Variation in the COMT gene: Implications for pain perception and pain treatment;Andersen;Pharmacogenomics,2009

2. COMT (Val158Met) polymorphism is not associated to neuropathic pain in a Spanish population;Armero;Eur J Pain,2005

3. Association study between clinical response to rizatriptan and some candidate genes;Asuni;J Headache Pain,2007

4. COMT Val108/158Met genotype affects the mu-opioid receptor system in the human brain: Evidence from ligand-binding, G-protein activation and preproenkephalin mRNA expression;Berthele;Neuroimage,2005

5. The catechol-O-methyltransferase polymorphism: Relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes;Bilder;Neuropsychopharmacology,2004

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of COMT (rs4680) and OPRM1 (rs1799971) on Cancer Pain, Opioid Dose, and Adverse Effects;Journal of Palliative Medicine;2024-09-10

2. The impact of genetic factors on the response to migraine therapy;Reviews in the Neurosciences;2024-06-11

3. Interplay Between Genetic Variants and Morphine: Toward Personalized Medicine in Cancer Pain Management;Interdisciplinary Cancer Research;2024

4. Effect of gene variants on opioid dose, pain and adverse effect outcomes in advanced cancer: an explorative study;Pharmacogenomics;2023-12

5. New management strategies for primary headache disorders: Insights from P4 medicine;Heliyon;2023-11